Core Viewpoint - Zhonghong Medical's subsidiary, Kelong Medical, is set to be selected for the volume-based procurement project for medical consumables in the central region of Xinjiang Uygur Autonomous Region, which will prioritize the use of its products in local medical institutions [1] Group 1 - Zhonghong Medical announced that Kelong Medical participated in the second batch of volume-based procurement for medical consumables in the central alliance of Xinjiang Uygur Autonomous Region [1] - The selected products include disposable vacuum blood collection tubes and disposable venous blood sampling needles [1] - During the procurement period, medical institutions in the procurement area will give priority to using the products proposed for selection by the company [1]

一、拟中选产品基本情况 证券代码：300981 证券简称：中红医疗 公告编号：2025-040 中红普林医疗用品股份有限公司 关于子公司参与集中带量采购项目拟中选的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 中红普林医疗用品股份有限公司（以下简称"公司"）控股子公司江西科伦 医疗器械制造有限公司（以下简称"科伦医械"）于近期参加新疆维吾尔自治区 中部联盟（第二批）医用耗材带量联动采购项目的投标工作。根据新疆维吾尔自 治区中部联盟（第二批）医用耗材带量联动采购中选结果显示，科伦医械部分产 品拟中选上述集中带量采购项目。现将相关情况公告如下： | 采购产品 | 产品分组 | 规格型号 | 注册证号 | 注册分类 | 适用范围 | 拟中选价 | 拟供应 | | --- | --- | --- | --- | --- | --- | --- | --- | | | | | | | | 格及数量 | 地区 | | | | 2ml、3ml、4ml、 | | | | | | | | 血清管（橘 | 5ml、10ml 血清管 | | | | | | | | 红色/红 ...

Group 1: Company Performance and Financials - In 2024, the company achieved a revenue of 245,665.07 million CNY, with a net profit of -8,712.89 million CNY [7] - In Q1 2025, the company reported a revenue of 62,915.00 million CNY and a net profit of 1,892.11 million CNY [7] Group 2: Growth Drivers - The main growth drivers include the expanding market for medical devices due to rising health awareness and consumption levels [3] - The company is enhancing its product matrix, maintaining a leading position in disposable nitrile gloves and increasing the proportion of high-margin products [3] - Continuous improvement in both domestic and international sales capabilities is expected to support future performance [3] Group 3: Industry Outlook - The medical device industry is anticipated to grow due to the exit of outdated production capacities and stable global demand [4] - The global healthcare market is projected to maintain stable growth, supported by national strategies prioritizing healthcare technology [8] Group 4: Strategic Initiatives - The company plans to focus on R&D, market expansion, quality assurance, and cost reduction to improve profitability [6] - There is an ongoing effort to explore mergers and acquisitions to enhance growth and optimize product structure [6] Group 5: Challenges and Market Sentiment - The company's stock has been trading below its issue price and net asset value, with three consecutive years of losses [6] - Market sentiment, industry dynamics, and operational performance are influencing the stock price [6]

北京德恒律师事务所 关于中红普林医疗用品股份有限公司 2024 年年度股东大会的 法律意见 北京市西城区金融街 19 号富凯大厦 B 座 12 层 电话:010-52682888 传真:010-52682999 邮编:100033 北京德恒律师事务所 关于中红普林医疗用品股份有限公司 2024 年年度股东大会的法律意见 （三）公司于2025年4月23日在巨潮资讯网（http://www.cninfo.com.cn） 公布的《中红普林医疗用品股份有限公司关于召开 2024 年年度股东大会的通知》 （以下简称"《股东大会的通知》"）； 北京德恒律师事务所 关于中红普林医疗用品股份有限公司 2024 年年度股东大会的 法律意见 德恒 01G20250295-01 号 致：中红普林医疗用品股份有限公司 中红普林医疗用品股份有限公司（以下简称"公司"）2024 年年度股东大 会（以下简称"本次会议"）于 2025 年 5 月 14 日（星期三）召开。北京德恒律 师事务所（以下简称"德恒"）受公司委托，指派吴莲花律师、廖齐越律师（以 下简称"德恒律师"），根据《中华人民共和国证券法》（以下简称"《证券法》"）、 《中华人 ...

证券代码：300981 证券简称：中红医疗 公告编号：2025-039 中红普林医疗用品股份有限公司 2024 年年度股东大会决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 特别提示： 1. 本次股东大会没有出现否决提案的情形。 2. 本次股东大会不涉及变更以往股东大会已通过决议的情形。 一、会议召开情况和出席情况 1. 会议召开时间： 现场会议召开时间：2025 年 5 月 14 日（星期三）14:30； 网络投票时间：2025 年 5 月 14 日。其中，通过深交所交易系统进行网络投 票的时间为 2025 年 5 月 14 日 9:15－9:25，9:30－11:30 和 13:00－15:00；通 过深圳证券交易所互联网系统投票的具体时间为2025年5月14日9:15－15:00。 2. 现场会议召开地点：北京经济技术开发区科创六街 87 号四楼会议室。 3. 会议召开方式：现场表决与网络投票相结合的方式。 4. 会议召集人：公司董事会。 5. 会议主持人：董事长桑树军先生。 6. 本次股东大会的召集及召开符合《中华人民共和国公司法》《中红普林 ...

证券代码：300981 证券简称：中红医疗 公告编号：2025-038 中红普林医疗用品股份有限公司 关于更换持续督导保荐代表人的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 中红普林医疗用品股份有限公司 董事会 中红普林医疗用品股份有限公司（以下简称"公司"）于近日收到公司首次 公开发行股票并在创业板上市的保荐机构国泰海通证券股份有限公司（以下简称 "国泰海通证券"）出具的《国泰海通证券股份有限公司关于更换中红普林医疗 用品股份有限公司持续督导保荐代表人的函》，国泰海通证券原委派张子慧先生、 雷浩先生为公司 IPO 项目保荐代表人，负责保荐工作及持续督导工作。由于原保 荐代表人张子慧先生因工作安排原因，无法继续从事公司的持续督导工作，为保 证持续督导工作的有序进行，国泰海通证券现委派保荐代表人邓伟先生接替张子 慧先生继续履行持续督导工作，保荐代表人邓伟先生简历详见附件。邓伟先生将 接替张子慧先生作为国泰海通证券保荐代表人，参加公司于 2025 年 5 月 15 日 (星期四)15:00-16:00 举办的 2024 年度暨 2025 年第一季度业绩说 ...

证券代码：300981 证券简称：中红医疗 公告编号：2025-037 中红普林医疗用品股份有限公司 关于为子公司提供担保的进展公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 一、担保情况概述 中红普林医疗用品股份有限公司（以下简称"公司"）分别于 2024 年 12 月 9 日、2024 年 12 月 25 日召开第四届董事会第四次会议及第四届监事会第四次会 议、2024 年第三次临时股东大会，审议通过了《关于公司及子公司 2025 年度向 银行申请综合授信额度暨公司为子公司申请综合授信额度提供担保的议案》，同 意公司为控股子公司 2025 年度向金融机构申请的授信额度提供担保，其中，为 资产负债率 70%（含）以上的控股子公司提供担保额度为不超过 15 亿元，为资 产负债率低于 70%的控股子公司提供担保额度为不超过 10 亿元，担保额度总计 不超过 25 亿元。具体内容详见《关于公司及子公司 2025 年度向银行申请综合授 信额度暨公司为子公司申请综合授信额度提供担保的公告》（公告编号：2024- 083）。 二、担保进展情况 7. 经营范围：生产 ...

中红医疗（300981）公告，子公司江西科伦医疗器械制造有限公司近期取得国家药品监督管理局颁发的 《医疗器械变更注册(备案)文件》。此次变更涉及一次性使用输液用肝素帽，注册分类为Ⅲ类，变更内 容为产品技术要求。本文件与原注册证共同使用。上述注册证变更是在原有基础上进行的相应变更，对 公司未来业绩的影响尚无法预测。 ...

Focus Events - The International Monetary Fund (IMF) has revised the global economic growth forecast for 2025 down to 2.8% from an earlier estimate of 3.3%, primarily due to the abrupt changes in U.S. tariff policies and the resulting high policy uncertainty [1] - The Shanghai Stock Exchange held a special training session on market value management for nearly 50 state-owned enterprises, focusing on guidelines from the China Securities Regulatory Commission [1] Macro News - The State Administration of Foreign Exchange emphasized the need to correct market pro-cyclical behaviors to prevent excessive exchange rate fluctuations, highlighting the recent volatility in the international financial market due to U.S. unilateralism and protectionism [2] Industry Dynamics - In the first quarter, China's equipment manufacturing industry saw a year-on-year increase in added value of 10.9%, contributing 3.5 percentage points to overall industrial production growth, with nearly 70% of key products experiencing production growth [3] - High-tech manufacturing added value grew by 9.7% year-on-year, with significant growth in sectors such as fiber optics, aerospace equipment, and integrated circuit manufacturing, all exceeding 20% [4] - A medium-sized gold mine was discovered in Hami, Xinjiang, with proven reserves of 5.8 tons, meeting the criteria for a medium-sized mine [5] Company Focus - BYD announced a profit distribution plan for 2024, proposing a cash dividend of RMB 39.74 per 10 shares and a stock bonus of 8 shares plus a capital reserve conversion of 12 shares for every 10 shares held, totaling approximately RMB 120.77 billion in cash dividends [10] - Huawei launched the industry's first all-liquid-cooled megawatt-level supercharger, which can output 2400A continuously and charge approximately 20 kWh in one minute [7] - China Mobile reported a 3.5% year-on-year increase in net profit for the first quarter, with total revenue of RMB 263.8 billion, remaining stable compared to the previous year [19] - ZTE Corporation's net profit for the first quarter decreased by 11% year-on-year, with revenue of RMB 32.968 billion, reflecting a 7.82% increase [20] - Pop Mart announced a revenue growth of 165% to 170% year-on-year for the first quarter, with domestic revenue increasing by 95% to 100% and overseas revenue soaring by 475% to 480% [21] - Xinlei Co. reported a staggering 3015% year-on-year increase in net profit for the first quarter, attributed to the recognition of relocation gains [23] - Zhonghong Medical's first-quarter net profit surged by 1370% year-on-year, with revenue of RMB 629 million, marking a 15.45% increase [24]

Market Overview - The market is currently experiencing narrow fluctuations and remains in a state of consolidation [1][24] - Major U.S. stock indices rebounded significantly, with the Dow Jones up 2.66%, S&P 500 up 2.51%, and Nasdaq up 2.71%, marking the largest single-day gains in recent weeks [3] Economic Forecasts - The International Monetary Fund (IMF) has significantly downgraded global economic growth forecasts, predicting a decline to 2.8% in 2025 and 3% in 2026, down from earlier estimates of 3.3% for both years [4] - The U.S. economic growth forecast for 2025 has been reduced to 1.8%, with a 40% probability of recession, up from 27% previously [4] Corporate Developments - Baidu released an AI white paper and action plan focusing on generative AI patent layout [9] - Boeing agreed to sell part of its digital aviation solutions business to Thoma Bravo for $10.55 billion [7] - Gree Electric's shareholders approved the re-election of Dong Mingzhu as chairman, with a dividend plan of 10 yuan per 10 shares [12] - Meituan's self-developed fourth-generation drone received a nationwide operational certificate for low-altitude logistics [13] Financial Performance - Newye Semiconductor reported a 384.54% increase in net profit for Q1 2025, with revenue of 4.052 billion yuan, up 264.13% [20] - Hailanxin's Q1 2025 net profit surged by 1324.75%, driven by project completions [21] - Zhonghong Medical's Q1 2025 net profit increased by 1370% [22] - Erkang Pharmaceutical reported a net profit of 28.11 million yuan for Q1 2025, up 868.91% [23] Industry Trends - The pharmaceutical sector is expected to continue its upward trend due to improved fundamentals and technological advancements [24]